quinazolines has been researched along with Recrudescence in 65 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (6.15) | 18.7374 |
| 1990's | 4 (6.15) | 18.2507 |
| 2000's | 18 (27.69) | 29.6817 |
| 2010's | 36 (55.38) | 24.3611 |
| 2020's | 3 (4.62) | 2.80 |
| Authors | Studies |
|---|---|
| Ardeshna, K; Beckmann, G; Buvaylo, V; Childs, BH; Chong, G; Gorbatchevsky, I; Haaber, J; Haioun, C; Hawkes, E; Hiemeyer, F; Lenz, G; Lippert, S; Peña, C; Piraino, P; Salles, G; Seog Heo, D; Shi, W; Thye Lim, S; Verhoef, G | 1 |
| Carlo-Stella, C; Magagnoli, M; Santoro, A | 1 |
| Baker, R; Bondarenko, I; Bouabdallah, K; Cao, A; Capra, M; Childs, BH; Feng, J; Galiulin, R; Geissler, K; Hamed, A; Hiemeyer, F; Jin, J; Jurczak, W; Lazaroiu, M; Li, W; Lin, T; Lv, F; Matasar, MJ; Mehra, A; Özcan, M; Sapunarova, K; Saydam, G; Shi, Y; Soler, LM; Szomor, Á; Uchida, T; Wang, MC; Yañez, E; Zhang, Q; Zinzani, PL | 1 |
| Assouline, SE; Bouabdallah, K; Bron, D; Childs, BH; Cunningham, D; Dreyling, M; Garcia-Vargas, J; Giurescu, M; Gorbatchevsky, I; Hiemeyer, F; Koechert, K; Linton, K; Liu, L; Morschhauser, F; Neves, M; Peña, C; Thieblemont, C; Verhoef, G; Vitolo, U; Zinzani, PL | 1 |
| Ahn, JH; Ahn, JS; Han, HS; Im, SA; Im, YH; Jung, KH; Kang, J; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Sohn, JH | 1 |
| Eltantawy, A; Evans, K; Sebea, E; Vallejos, X | 1 |
| Lv, J; Nong, J; Qin, N; Wang, J; Wu, Y; Yang, X; Zhang, H; Zhang, Q; Zhang, S | 1 |
| Ezaki, T; Iguchi, T; Ito, S; Koga, T; Nozoe, E; Nozoe, T; Ohga, T | 1 |
| Aerts, JG; Biesma, B; Burgers, S; Codrington, H; Dalesio, O; Dingemans, AM; Groen, HJ; Lankheet, NA; Smit, EF; Vincent, AD | 1 |
| Bass, SA; Gibson, AM; Khurana Hershey, GK; Xiao, C; Zhang, Z | 1 |
| Amler, L; Eaton, K; Fine, BM; Gitlitz, B; Hicks, R; Hughes, B; Loecke, D; Mileshkin, L; Mitchell, P; Pirzkall, A; Townley, P; Wood, K | 1 |
| Alden, CM; Bashoura, L; Eapen, GA; Faiz, SA; Herbst, RS; Hong, WK; Jack Lee, J; Jimenez, CA; Liu, DD; Marom, EM; Massarelli, E; Mino, B; Morice, RC; Onn, A; Tran, HT; Wistuba, II | 1 |
| Collins, GP; Eyre, TA; Hatton, C; Linton, KM; Radford, J; Soilleux, E; Vallance, GD | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Cameron, MG; Kersten, C; Laird, B; Mjåland, S | 1 |
| Brown, N; Clifton-Hadley, L; Dungey, F; Hopkins, K; Jeffries, S; Khan, I; Krell, D; McBain, C; Mulholland, P; Nash, S; Phillips, M; Sanghera, P; Saran, F; Smith, P; Wanek, K | 1 |
| Ali, SM; Allen, JM; Erlich, RL; Miller, VA; Ou, SI; Ross, JS; Schrock, AB; Stephens, PJ; Vafai, D | 1 |
| Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M | 1 |
| Beau-Faller, M; Gaub, MP; Guerin, E; Jeung, MY; Legrain, M; Mennecier, B; Molard, A; Neuville, A; Oudet, P; Quoix, E; Ruppert, AM; Voegeli, AC | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Awada, A; Bachelot, T; Blackwell, K; DeSilvio, M; Johnston, S; Kaufman, B; Salazar, V; Spector, N; Trudeau, M; Westlund, R; Zaks, T | 1 |
| Annunziata, CM; Calvo, K; Choyke, P; Kimm, D; Kohn, EC; Kotz, H; Minasian, L; Steinberg, SM; Walker, AJ; Wood, BJ; Yu, M | 1 |
| Cheng, N; de Jong, MC; Jiang, L; Li, F; Li, N; Li, Q; Mao, H; Pawlik, TM; Zhou, Y | 1 |
| Ahn, JS; Ahn, MJ; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW; Yun, J | 1 |
| Alber, JA; Ding, J; Mas Lopez, L; Monk, BJ; Oaknin, A; Pandite, LN; Stutts, MW; Tarpin, C; Termrungruanglert, W; Zarba, JJ | 1 |
| Chopra, A; Ku, GY; Lopes, Gde L | 1 |
| de Marinis, F; Gridelli, C; Rossi, A; Venturino, P | 1 |
| Andrade, RJ; Hallal, H; López Martín, A; Titos-Arcos, JC | 1 |
| Morio, A; Ninomiya, H; Sunada, K | 1 |
| Kitamura, Y; Sakakura, N; Suyama, M; Uchida, T | 1 |
| Murphy, M; Stordal, B | 1 |
| Abe, H; Aikawa, E; Akiba, J; Azuma, K; Kage, M; Kawahara, A; Nakashima, K; Sumi, A; Taira, T; Takamori, S; Yamaguchi, T | 1 |
| Arcila, ME; Azzoli, CG; Janjigian, YY; Kass, SL; Kris, MG; Ladanyi, M; Miller, VA; Oxnard, GR; Pao, W; Riely, GJ; Sima, CS | 1 |
| Albain, KS; Clementz, AG; Meeke, K; Miele, L; Osipo, C; Pandya, K; Roberts, J; Rogowski, A | 1 |
| Amadori, S; Berman, E; Cahn, JY; Faderl, S; Goudie, A; Ifrah, N; Jabbour, E; Jongen-Lavrencic, M; Kantarjian, H; Löwenberg, B; Martinelli, G; Muus, P; Ossenkoppele, G; Rigaudeau, S; Rousselot, P; Sonneveld, P; Stockman, P | 1 |
| Koshiishi, H; Takahashi, E; Takahashi, M | 1 |
| Arola, M; Kähkönen, M; Lohi, O; Parto, K; Vettenranta, K; Vornanen, M | 1 |
| Hansen, KH; Hansen, NC; Hansen, O; Kristiansen, C; Olsen, KE | 1 |
| Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY | 1 |
| Boockvar, JA; Christos, P; Kaplan, R; Kesavabhotla, K; Lavi, E; Mubita, L; Pannullo, SC; Scheff, R; Schlaff, CD; Shin, B; Tsiouris, AJ | 1 |
| Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
| Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY | 1 |
| Hjalmas, K; Jünemann, KP; Kramer, G; Madersbacher, H; Marschall-Kehrel, AD; Mürtz, G | 1 |
| Bamias, A; Efstathiou, E; Stratigos, A; Zorzou, MP | 1 |
| Bostrom, B; Drehner, D; Lander, T; Marker, S; Sidman, J | 1 |
| Hargreave, TB; McNeill, SA; Roehrborn, CG | 1 |
| Bauer, JA; Cerny, T; Egli, F; Gillessen, S; Jermann, M; Joerger, M; Morant, R; Pless, M; Rhyner, K; Salzberg, M; Stahel, RA | 1 |
| Arciero, CA; Chen, X; Darcy, KM; Decesare, SL; Godwin, AK; Lee, RB; Lewandowski, G; Schilder, RJ; Sill, MW; Wu, H | 1 |
| Edakuni, N; Inayama, M; Kakiuchi, S; Muguruma, H; Nakataki, E; Nishikubo, N; Ohtsuka, S; Sone, S; Tomimoto, H; Yano, S | 1 |
| Bigner, DD; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lyons, P; McLendon, RE; Ochs, JS; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Smith, RP; Swaisland, AJ; Tourt-Uhlig, S; Vredenburgh, JJ | 1 |
| Sabbatini, P | 1 |
| Chen, E; Dancey, J; Hedley, D; Ho, J; Major, P; Moore, MJ; Nicklee, T; Oza, AM; Pond, GR; Siu, LL; Townsley, CA; Tsao, M | 1 |
| Hasegawa, Y; Hashimoto, N; Honda, T; Imaizumi, K; Kawabe, T; Nagasaka, T; Shimokata, K | 1 |
| Castellano, A; De Ioris, MA; De Laurentis, C; Dominici, C; Donfrancesco, A; Garganese, MC; Ilari, I; Jenkner, A; Milano, GM | 1 |
| Asahina, H; Konishi, J; Nishimura, M; Suzuki, M; Yamazaki, K | 1 |
| Chernoff, SG; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Ruiz-Reyes, G | 1 |
| Comet, D; Grange, JC; Lukacs, B | 1 |
| de Vos, AJ; Shiels, I; Stewart, NP | 1 |
| Alvarado, C; Dubowy, R; Kamen, B; Pappo, A; Rao, S; Ravindranath, Y; Vega, R; Vietti, T; Whitehead, VM | 1 |
| Faber, HJ; Sprenger, HG; Weits, J | 1 |
| Deng, BZ; Hu, YM; Kuang, MS; Liu, FA; Wang, XX; Zhu, QP | 1 |
| Kovacs, JA; Masur, H | 1 |
| Johansson, EA; Niemi, KM; Ranki, A | 1 |
5 review(s) available for quinazolines and Recrudescence
| Article | Year |
|---|---|
Copanlisib for the treatment of adults with relapsed follicular lymphoma.
Topics: Administration, Intravenous; Adult; Antineoplastic Agents; Humans; Lymphoma, Follicular; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence | 2020 |
Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Topics: Administration, Intravenous; Aged; Angiogenesis Inhibitors; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence | 2019 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
Pneumocystis carinii pneumonia: therapy and prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Dapsone; Drug Combinations; Drug Therapy, Combination; Humans; Pentamidine; Pneumonia, Pneumocystis; Pyrimethamine; Quinazolines; Recurrence; Sulfadiazine; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate | 1988 |
25 trial(s) available for quinazolines and Recrudescence
| Article | Year |
|---|---|
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; CD79 Antigens; Female; High-Throughput Nucleotide Sequencing; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence | 2020 |
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Rituximab | 2021 |
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Female; Humans; Lymphoma; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Recurrence; Survival Analysis | 2017 |
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recurrence; Republic of Korea; Survival Analysis | 2018 |
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pemetrexed; Quinazolines; Recurrence; Taxoids | 2013 |
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recurrence; Tomography, X-Ray Computed | 2014 |
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catheters, Indwelling; Humans; Lung Neoplasms; Middle Aged; Piperidines; Pleural Effusion, Malignant; Pleurodesis; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recurrence; Survival Rate; Time Factors; Treatment Outcome | 2014 |
A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Recurrence; Treatment Outcome | 2015 |
Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Pain Measurement; Panitumumab; Prospective Studies; Quinazolines; Recurrence; Young Adult | 2015 |
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Placebos; Quality of Life; Quinazolines; Recurrence; Safety; Vascular Endothelial Growth Factor A | 2016 |
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Recurrence; Survival Analysis | 2008 |
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Recurrence; Skin Diseases; Treatment Outcome | 2009 |
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cystadenocarcinoma, Serous; Drug Administration Schedule; ErbB Receptors; Female; Humans; Middle Aged; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Recurrence; Signal Transduction; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indazoles; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Retreatment; Sulfonamides; Uterine Cervical Neoplasms | 2010 |
Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-ce
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Recurrence; Research Design; Smoking; Taxoids | 2011 |
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Aurora Kinase B; Aurora Kinases; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Organophosphates; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Recurrence; Severity of Illness Index | 2011 |
Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.
Topics: Adult; Aged; Anticonvulsants; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Recurrence | 2012 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides | 2013 |
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Biomarkers; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Emergencies; Humans; Life Tables; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Recurrence; Urinary Catheterization; Urinary Retention | 2005 |
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2006 |
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Catalytic Domain; Cloning, Molecular; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Polymerase Chain Reaction; Protein Structure, Tertiary; Quinazolines; Recurrence; Time Factors; Treatment Outcome | 2005 |
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Glioma; Humans; Male; Middle Aged; Quinazolines; Recurrence; Sirolimus; Treatment Outcome | 2006 |
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Recurrence; Risk Factors; Signal Transduction; Survival Rate; Treatment Outcome | 2006 |
Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinazolines; Recurrence; Remission Induction; Trimetrexate | 1990 |
35 other study(ies) available for quinazolines and Recrudescence
| Article | Year |
|---|---|
Copanlisib (Aliqopa) for relapsed follicular lymphoma.
Topics: Antineoplastic Agents; Drug Costs; Drug Interactions; Humans; Lymphoma, Follicular; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Signal Transduction; Treatment Outcome | 2018 |
[Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retrospective Studies; Survival Analysis; Treatment Failure | 2013 |
[Combined therapy of lapatinib and capecitabine effective against local recurrence of breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2013 |
EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis.
Topics: Administration, Cutaneous; Allergens; Animals; Cells, Cultured; Chemokine CXCL1; Chemokine CXCL2; Dermatitis, Atopic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Interleukin-17; Interleukin-1beta; Interleukin-22; Interleukin-6; Interleukins; Keratinocytes; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Quinazolines; Recurrence; Signal Transduction; Skin; Specific Pathogen-Free Organisms; Th17 Cells | 2014 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Circulating Tumor DNA; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Profiling; Genome; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Neoplasm Metastasis; Oncogene Proteins, Fusion; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; Recurrence | 2017 |
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Quinazolines; Recurrence; Treatment Outcome | 2009 |
Epidermal growth factor receptor as a target for anti-proliferative treatment of proliferative cholangitis in hepatolithiasis.
Topics: Animals; Bromodeoxyuridine; Cell Division; Cholangitis; Collagen Type I; Disease Models, Animal; Enzyme Inhibitors; ErbB Receptors; fas Receptor; Fibrosis; Gene Expression; In Situ Nick-End Labeling; Ki-67 Antigen; Lithiasis; Male; Mucin 5AC; Quinazolines; Rats; Rats, Sprague-Dawley; Recurrence; Tyrphostins | 2011 |
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retreatment; Retrospective Studies; Treatment Failure | 2010 |
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity.
Topics: Aged, 80 and over; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Green Fluorescent Proteins; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Metastasis; Quinazolines; Recurrence | 2010 |
[Recurrent hepatocellular lesion due to alfuzosin].
Topics: Adrenergic alpha-1 Receptor Antagonists; Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Quinazolines; Recurrence | 2011 |
[A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence; Remission Induction; Tomography, X-Ray Computed | 2011 |
[Limitation of apoptosis induced by gefitinib in a long-surviving postoperative recurrent lung cancer case].
Topics: Aged; Apoptosis; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Recurrence; Remission Induction; Time Factors; Tomography, X-Ray Computed | 2011 |
Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Topics: Adult; Aged; Antibodies, Monoclonal; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Polymerase Chain Reaction; Quinazolines; Recurrence; Sensitivity and Specificity; Sequence Deletion | 2011 |
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence | 2011 |
Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.
Topics: Amyloid Precursor Protein Secretases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cyclic S-Oxides; Drug Resistance, Neoplasm; Female; Gene Targeting; Genes, erbB; Genes, erbB-2; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Receptors, Notch; Recurrence; Signal Transduction; Thiadiazoles; Trastuzumab | 2011 |
[A response to erlotinib hydrochloride in the case of post-operative recurrent thymoma].
Topics: Adult; Erlotinib Hydrochloride; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Recurrence; Thymoma; Thymus Neoplasms | 2011 |
Recurrent congenital fibrosarcoma with heart metastases.
Topics: Erlotinib Hydrochloride; Female; Fibrosarcoma; Heart Neoplasms; Humans; Infant; Oncogene Proteins, Fusion; Pregnancy; Protein Kinase Inhibitors; Quinazolines; Recurrence | 2012 |
Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multimodal Imaging; Mutation; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors | 2012 |
[A suggested treatment algorithm in nocturnal enuresis with emphasis on partial responders].
Topics: Adolescent; Algorithms; Behavior Therapy; Benzilates; Biofeedback, Psychology; Child; Child, Preschool; Combined Modality Therapy; Deamino Arginine Vasopressin; Enuresis; Female; Follow-Up Studies; Humans; Male; Outcome and Process Assessment, Health Care; Psychotherapy; Quinazolines; Recurrence; Retreatment; Treatment Failure; Urodynamics | 2004 |
Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Psoriasis; Quinazolines; Recurrence; Severity of Illness Index | 2004 |
Gefitinib therapy for life-threatening laryngeal papillomatosis.
Topics: Adolescent; Antiviral Agents; Bronchoscopy; ErbB Receptors; Gefitinib; Humans; Laryngeal Neoplasms; Male; Papilloma; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Recurrence; Treatment Outcome | 2005 |
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion; Quinazolines; Recurrence; Retreatment; Time Factors | 2005 |
New agents and new formulations for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Dioxoles; Erlotinib Hydrochloride; Female; Humans; Isoquinolines; Ovarian Neoplasms; Predictive Value of Tests; Quinazolines; Recurrence; Remission Induction; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A | 2005 |
Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biopsy; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Quinazolines; Recurrence | 2006 |
Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Female; Gefitinib; Humans; Neuroblastoma; Quinazolines; Radionuclide Imaging; Recurrence; Topotecan; Treatment Outcome | 2007 |
Recurrent gefitinib-induced interstitial lung disease.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2008 |
Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia.
Topics: Aged; Antineoplastic Agents; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Leg Ulcer; Platelet Aggregation Inhibitors; Quinazolines; Recurrence; Thrombocythemia, Essential | 1998 |
One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Family Practice; Follow-Up Studies; Humans; Male; Middle Aged; Postoperative Complications; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Quinazolines; Recurrence; Sickness Impact Profile; Urinary Retention; Urodynamics | 2000 |
Elimination of Theileria buffeli infections from cattle by concurrent treatment with primaquine phosphate and halofuginone lactate.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Apicomplexa; Cattle; Drug Therapy, Combination; Fluorescent Antibody Technique; Piperidines; Primaquine; Quinazolines; Quinazolinones; Recurrence; Splenectomy; Theileriasis | 1990 |
Relapse Pneumocystis carinii pneumonitis and adverse reaction to current therapy in patients with AIDS: trimetrexate as an alternative.
Topics: Acquired Immunodeficiency Syndrome; Adult; Folic Acid Antagonists; Humans; Male; Pneumonia, Pneumocystis; Quinazolines; Radiography; Recurrence; Trimetrexate | 1990 |
[Action of nitroquine on tissue schizonts of Plasmodium cynomolgi].
Topics: Animals; Antimalarials; Dapsone; Female; Macaca mulatta; Malaria; Male; Plasmodium; Quinazolines; Recurrence | 1986 |
Treatment of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Combinations; Folic Acid Antagonists; Humans; Methylprednisolone; Pentamidine; Pneumonia, Pneumocystis; Quinazolines; Recurrence; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate | 1987 |
Modification of lymphocyte subsets in Jessner's lymphocytic infiltration of the skin during proquazone treatment.
Topics: Adult; Antibodies, Monoclonal; Cell Movement; Female; Humans; Immunohistochemistry; Lymphocytes; Male; Middle Aged; Quinazolines; Recurrence; Skin Diseases | 1988 |